These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 9232605

  • 1. Matrix metalloproteinase inhibitors in the treatment of cancer.
    Brown PD.
    Med Oncol; 1997 Mar; 14(1):1-10. PubMed ID: 9232605
    [Abstract] [Full Text] [Related]

  • 2. Matrix metalloproteinase inhibitors.
    Wojtowicz-Praga SM, Dickson RB, Hawkins MJ.
    Invest New Drugs; 1997 Mar; 15(1):61-75. PubMed ID: 9195290
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.
    Jones L, Ghaneh P, Humphreys M, Neoptolemos JP.
    Ann N Y Acad Sci; 1999 Jun 30; 880():288-307. PubMed ID: 10415874
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Role of matrix metalloproteinases and their inhibitors in pancreatic cancer.
    Evans JD, Ghaneh P, Kawesha A, Neoptolemos JP.
    Digestion; 1997 Jun 30; 58(6):520-8. PubMed ID: 9438596
    [Abstract] [Full Text] [Related]

  • 7. Matrix metalloproteinase inhibitors: present achievements and future prospects.
    Denis LJ, Verweij J.
    Invest New Drugs; 1997 Jun 30; 15(3):175-85. PubMed ID: 9387040
    [Abstract] [Full Text] [Related]

  • 8. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review).
    Duffy MJ, McCarthy K.
    Int J Oncol; 1998 Jun 30; 12(6):1343-8. PubMed ID: 9592197
    [Abstract] [Full Text] [Related]

  • 9. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP).
    Murphy G, Cockett MI, Ward RV, Docherty AJ.
    Biochem J; 1991 Jul 01; 277 ( Pt 1)(Pt 1):277-9. PubMed ID: 1649600
    [Abstract] [Full Text] [Related]

  • 10. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
    Gallegos NC, Smales C, Savage FJ, Hembry RM, Boulos PB.
    Surg Oncol; 1995 Feb 01; 4(1):21-9. PubMed ID: 7780609
    [Abstract] [Full Text] [Related]

  • 11. Matrix metalloproteinases. Novel targets for directed cancer therapy.
    Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG.
    Drugs Aging; 1997 Sep 01; 11(3):229-44. PubMed ID: 9303281
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Leukemic cells (HL-60) produce a novel extracellular matrix-degrading proteinase that is not inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs).
    Dittmann KH, Lottspeich F, Ries C, Petrides PE.
    Exp Hematol; 1995 Feb 01; 23(2):155-60. PubMed ID: 7828672
    [Abstract] [Full Text] [Related]

  • 16. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
    Gallegos NC, Smales C, Savage FJ, Hembry RM, Boulos PB.
    Surg Oncol; 1995 Feb 01; 4(2):111-9. PubMed ID: 7551259
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours.
    Rooprai HK, Van Meter T, Rucklidge GJ, Hudson L, Everall IP, Pilkington GJ.
    Int J Oncol; 1998 Dec 01; 13(6):1153-7. PubMed ID: 9824624
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.